JP2010143932A5 - - Google Patents

Download PDF

Info

Publication number
JP2010143932A5
JP2010143932A5 JP2010002870A JP2010002870A JP2010143932A5 JP 2010143932 A5 JP2010143932 A5 JP 2010143932A5 JP 2010002870 A JP2010002870 A JP 2010002870A JP 2010002870 A JP2010002870 A JP 2010002870A JP 2010143932 A5 JP2010143932 A5 JP 2010143932A5
Authority
JP
Japan
Prior art keywords
antibody
srage
fragment
peptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010002870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010143932A (ja
Filing date
Publication date
Priority claimed from US08/948,131 external-priority patent/US6555651B2/en
Application filed filed Critical
Publication of JP2010143932A publication Critical patent/JP2010143932A/ja
Publication of JP2010143932A5 publication Critical patent/JP2010143932A5/ja
Pending legal-status Critical Current

Links

JP2010002870A 1997-10-09 2010-01-08 Ｒａｇｅのリガンド結合部位及びその使用 Pending JP2010143932A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/948,131 US6555651B2 (en) 1997-10-09 1997-10-09 Ligand binding site of rage and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000515619A Division JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用

Publications (2)

Publication Number Publication Date
JP2010143932A JP2010143932A (ja) 2010-07-01
JP2010143932A5 true JP2010143932A5 (enExample) 2010-11-18

Family

ID=25487337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000515619A Withdrawn JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用
JP2010002870A Pending JP2010143932A (ja) 1997-10-09 2010-01-08 Ｒａｇｅのリガンド結合部位及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000515619A Withdrawn JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用

Country Status (11)

Country Link
US (1) US6555651B2 (enExample)
EP (2) EP1023080B1 (enExample)
JP (2) JP2001519401A (enExample)
AT (1) ATE476192T1 (enExample)
AU (1) AU9795898A (enExample)
CY (1) CY1110884T1 (enExample)
DE (1) DE69841806D1 (enExample)
DK (1) DK1023080T3 (enExample)
ES (1) ES2351876T3 (enExample)
PT (1) PT1023080E (enExample)
WO (1) WO1999018987A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
ES2299267T3 (es) * 1998-10-06 2008-05-16 The Trustees Of Columbia University In The City Of New York Nueva proteina extracelular ligante de rage (en-rage) y sus usos.
JP2003507013A (ja) * 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US7087632B2 (en) 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
EP1724589A3 (en) * 2000-05-30 2007-04-25 TransTech Pharma Inc. Methods to identify compounds that modulate rage
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
EP1377295A4 (en) 2001-03-05 2007-05-09 Transtech Pharma Inc CARBOXYL ACID DERIVATIVES THERAPEUTIC AGENTS
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
JP5188804B2 (ja) * 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
AU2005271449A1 (en) * 2004-08-03 2006-02-16 The Trustees Of Columbia University In The City Of New York RAGE fusion proteins and methods of use
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US9291621B2 (en) * 2005-01-18 2016-03-22 AbbVie Deutschland GmbH & Co. KG AGER-peptides and use thereof
WO2006077101A2 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg Ager-peptide und deren verwendung
EP1869464A4 (en) * 2005-03-17 2009-12-02 Univ Columbia RAGE-DIAPHANOUS INTERACTION AND CORRESPONDING COMPOSITIONS AND METHODS
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
JP2008539235A (ja) * 2005-04-29 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症反応によって特徴付けられる病状を処置するためのペプチドおよびペプチド模倣物
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
CA2634908C (en) * 2005-12-23 2015-05-19 Gcoder Systems Ab Positioning pattern
KR20080105066A (ko) * 2006-02-09 2008-12-03 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
KR101361355B1 (ko) 2007-06-14 2014-02-12 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
KR20110139292A (ko) 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
JP5894540B2 (ja) 2010-02-18 2016-03-30 ブイティーブイ・セラピューティクス・エルエルシー フェニル−ヘテロアリール誘導体とその使用の方法
JP5999542B2 (ja) * 2010-11-18 2016-09-28 国立研究開発法人農業・食品産業技術総合研究機構 リガンド様活性を有する分子の検出方法
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
KR101595630B1 (ko) * 2013-01-18 2016-02-18 성균관대학교산학협력단 Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
CA2182731A1 (en) 1994-02-03 1995-08-10 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
EP0870040A2 (en) * 1995-12-29 1998-10-14 Chiron Corporation Gene delivery vehicle-targeting ligands
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
AU726379B2 (en) * 1996-02-21 2000-11-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant ribonuclease proteins
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof

Similar Documents

Publication Publication Date Title
JP2010143932A5 (enExample)
JP2013523703A5 (enExample)
JP2014132019A5 (enExample)
JP2012531046A5 (enExample)
JP2014513951A5 (enExample)
SMT201500125B (it) Anticorpi umani che legano il gene di attivazione dei linfociti-3 (lag-3) e loro usi
JP2013172734A5 (enExample)
JP2015520667A5 (enExample)
JP2012098988A5 (enExample)
DK3029066T3 (da) Antistoffer med modificerede isoelektriske punkter
BRPI0921892A2 (pt) catalisadores de paládio-ouro de suporte e preparação de acetato de vinila com os mesmos
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
JP2014518898A5 (enExample)
IL226427A0 (en) Anti ccr4 antibodies and uses thereof
JP2013540702A5 (enExample)
WO2015006728A3 (en) Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
WO2008094621A3 (en) Methods for allergen detection
WO2011056958A3 (en) Detection of traumatic brain injury
JP2015516943A5 (enExample)
EP3004375A4 (en) Protease-responsive peptide biosensors and methods for analyte detection
JP2011236418A5 (enExample)
CN301923368S (zh) 电动轿车车身（ej04 c）
CN301853019S (zh) 电动轿车车身（ej02 c）
CN301845331S (zh) 电动轿车车身（ej02 d）
CN301937634S (zh) 电动轿车车身（ej02 a）